Novel Cardiovascular Risk Biomarkers in Carotid Atherogenesis

References

• Quercioli A , MontecuccoF, BertolottoMet al. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling. Eur. J. Clin. Invest.40(7), 645–654 (2010).
   PubMed Web of Science ®Google Scholar
• Quercioli A , MachF, BertolottoMet al. Receptor activator of NF- kappaB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb. Haemost.107(1), 124–139 (2012).
   PubMed Web of Science ®Google Scholar
• Morimoto J , KonS, MatsuiY, UedeT. Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr. Drug Targets11(4), 494–505 (2010).
   PubMed Web of Science ®Google Scholar
• Carbone F , VuilleumierN, BurgerFet al. Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke. Eur. J. Clin. Invest.45(6), 579–586 (2015).
   PubMed Web of Science ®Google Scholar
• Wolak T . Osteopontin – a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis236(2), 327–337 (2014).
   PubMed Web of Science ®Google Scholar
• Hamias R , VolvichL, ParanEet al. Low osteopontin n-terminal fragment and carotid plaque stability associated with statin or antiplatelet therapy. Curr. Vasc. Pharmacol.14(3), 288–294 (2016).
   PubMed Web of Science ®Google Scholar
• Carbone F , RigamontiF, BurgerFet al. Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. Int. J. Cardiol.255, 195–199 (2018).
   PubMed Web of Science ®Google Scholar
• Zwakenberg SR , Van Der SchouwYT, SchalkwijkCG, SpijkermanAMW, BeulensJWJ. Bone markers and cardiovascular risk in Type 2 diabetes patients. Cardiovasc. Diabetol.17(1), 45 (2018).
   PubMedGoogle Scholar
• Gomez-Ambrosi J , CatalanV, RamirezBet al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J. Clin. Endocrinol. Metab.92(9), 3719–3727 (2007).
   PubMed Web of Science ®Google Scholar
• Sawaki D , CzibikG, PiniMet al. Visceral adipose tissue drives cardiac aging through modulation of fibroblast senescence by osteopontin production. Circulation doi:10.1161/CIRCULATIONAHA.117.031358 (2018) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Sabater M , Moreno-NavarreteJM, OrtegaFJet al. Circulating pigment epithelium-derived factor levels are associated with insulin resistance and decrease after weight loss. J. Clin. Endocrinol. Metab.95(10), 4720–4728 (2010).
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM , OrtegaF, SerinoMet al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int. J. Obes.36(11), 1442–1449 (2012).
   PubMed Web of Science ®Google Scholar
• Zhao G , HuM, LiCet al. Osteopontin contributes to effective neutrophil recruitment, IL-1beta production and apoptosis in Aspergillus fumigatus keratitis. Immunol. Cell. Biol.96(4), 401–412 (2018).
   PubMed Web of Science ®Google Scholar
• Ge Q , RuanCC, MaYet al. Osteopontin regulates macrophage activation and osteoclast formation in hypertensive patients with vascular calcification. Sci. Rep.7, 40253 (2017).
   PubMed Web of Science ®Google Scholar
• Hag AM , PedersenSF, ChristoffersenCet al. (18)F-FDG PET imaging of murine atherosclerosis: association with gene expression of key molecular markers. PLoS ONE7(11), e50908 (2012).
   PubMed Web of Science ®Google Scholar
• Qiao H , WangY, ZhangRet al. MRI/optical dual-modality imaging of vulnerable atherosclerotic plaque with an osteopontin-targeted probe based on Fe3O4 nanoparticles. Biomaterials112, 336–345 (2017).
   PubMed Web of Science ®Google Scholar
• Hernandez P , WhittyC, John WardaleR, HensonFM. New insights into the location and form of sclerostin. Biochem. Biophys. Res. Commun.446(4), 1108–1113 (2014).
   PubMed Web of Science ®Google Scholar
• Gaudio A , PriviteraF, PulvirentiI, CanzonieriE, RapisardaR, FioreCE. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with Type 2 diabetes mellitus. Diab. Vasc. Dis. Res.11(1), 48–52 (2014).
   PubMed Web of Science ®Google Scholar
• Gaudio A , FioreV, RapisardaRet al. Sclerostin is a possible candidate marker of arterial stiffness: results from a cohort study in Catania. Mol. Med. Rep.15(5), 3420–3424 (2017).
   PubMed Web of Science ®Google Scholar
• Morales-Santana S , Garcia-FontanaB, Garcia-MartinAet al. Atherosclerotic disease in Type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care36(6), 1667–1674 (2013).
   PubMed Web of Science ®Google Scholar
• He XW , WangE, BaoYYet al. High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke. Atherosclerosis253, 22–28 (2016).
   PubMed Web of Science ®Google Scholar
• Krishna SM , SetoSW, JoseRJet al. Wnt signaling pathway inhibitor sclerostin inhibits angiotensin ii-induced aortic aneurysm and atherosclerosis. Arterioscler. Thromb. Vasc. Biol.37(3), 553–566 (2017).
   PubMed Web of Science ®Google Scholar
• Badimon L , Borrell-PagesM. Wnt signaling in the vessel wall. Curr. Opin. Hematol.24(3), 230–239 (2017).
   PubMed Web of Science ®Google Scholar
• Fruhbeck G . Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat. Rev. Endocrinol.11(8), 465–477 (2015).
   PubMed Web of Science ®Google Scholar